Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

被引:25
|
作者
Nicholas, Anthony P.
机构
[1] Univ Alabama Birmingham, Sparks Ctr, Dept Neurol, Birmingham, AL 35294 USA
[2] Vet Adm Med Ctr, Birmingham, AL USA
关键词
dyskinesia; levodopa; MPTP; Parkinson's disease;
D O I
10.1002/mds.21235
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The present study examines the motor responses of 10- to 12-month-old, male C57 mice that were either given intraperitoneal (IP) injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 30 mg/kg per day) or vehicle for 10 consecutive days, followed by IP injections of levodopa (200 mg/ka) plus carbidopa (25 mg/ka). Five days of MPTP exposure resulted in the Straub tail phenomenon and pronounced hypokinesia. However, during the next 5 days, motor activity returned to baseline, even with continued MPTP treatment. After 10 to 14 days of rest, all mice were then treated with levodopa/carbidopa twice daily for multiple, consecutive days. However, only the previously MPTP-treated animals became hyperkinetic, as compared to levodopa-treated control animals that were not previously exposed to MPTP. Abnormal activity included scratching, running, gnawing, and jumping movements. Hyperactivity lasted for approximately 2 hours after each levodopa injection and then returned to baseline, but the amount of hyperkinesia increased with additional days of levodopa treatment, even though the daily levodopa dose was not changed. These results demonstrate that levodopa can cause reproducible hyperactivity in mice that were previously exposed to MPTP. (C) 2006 Movement Disorder Society.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 50 条
  • [1] Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys
    Samadi, P
    Grégoire, L
    Rouillard, C
    Bédard, PJ
    Di Paolo, T
    Lévesque, D
    ANNALS OF NEUROLOGY, 2006, 59 (02) : 282 - 288
  • [2] Estradiol and dehydroepiandrosterone potentiate levodopa-induced locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys
    Nancy Bélanger
    Laurent Grégoire
    Paul J. Bédard
    Thérèse Di Paolo
    Endocrine, 2003, 21 : 97 - 101
  • [3] Estradiol and dehydroepiandrosterone potentiate levodopa-induced locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys
    Bélanger, N
    Grégoire, L
    Bédard, PJ
    Di Paolo, T
    ENDOCRINE, 2003, 21 (01) : 97 - 101
  • [4] LEVODOPA-INDUCED DYSKINESIA AND RESPONSE FLUCTUATIONS IN PRIMATES RENDERED PARKINSONIAN WITH 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP)
    CLARKE, CE
    SAMBROOK, MA
    MITCHELL, IJ
    CROSSMAN, AR
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1987, 78 (03) : 273 - 280
  • [5] THE SIGNIFICANCE OF 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE
    MARSDEN, CD
    JENNER, PG
    CIBA FOUNDATION SYMPOSIA, 1987, 126 : 239 - 256
  • [6] Mutagenic activity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
    Ulanowska, K
    Wegrzyn, G
    JOURNAL OF APPLIED GENETICS, 2006, 47 (01) : 85 - 87
  • [7] PLACENTAL TOXICITY OF 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) IN MICE
    SCHMAHL, W
    USLER, B
    TOXICOLOGY, 1991, 67 (01) : 63 - 74
  • [8] EFFECTS OF 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE ON RECTAL TEMPERATURE IN MICE
    SATOH, N
    MATSUMURA, T
    YONEZAWA, A
    TADANO, T
    KISARA, K
    ARAI, Y
    KINEMUCHI, H
    JAPANESE JOURNAL OF PHARMACOLOGY, 1987, 43 : P75 - P75
  • [9] Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice
    Turmel, H
    Hartmann, A
    Parain, K
    Douhou, A
    Srinivasan, A
    Agid, Y
    Hirsch, EC
    MOVEMENT DISORDERS, 2001, 16 (02) : 185 - 189
  • [10] Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity
    Hare, Dominic J.
    Adlard, Paul A.
    Doble, Philip A.
    Finkelstein, David I.
    METALLOMICS, 2013, 5 (02) : 91 - 109